Clinical Efficacy of Bleomycin, Cyclophosphamide, Vindesine, Ara-C and Dexamethasone for Treatment of Patients with Relapsed Refractory Diffuse Large B Cell Lymphoma.
- Author:
Hong WAN
1
;
Gang FENG
2
;
Xiao-Juan WANG
2
;
Fang WANG
2
;
Xue-Lan HUANG
2
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Recurrence; Treatment Outcome; Vincristine; Vindesine
- From: Journal of Experimental Hematology 2015;23(3):693-695
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the clinical efficacy of bleomycin, cyclophosphamide, vindesine, Ara-C and dexamethasone(BACOD) for treatment of patients with relapsed/refractory diffuse large B cell lymphoma.
METHODSA total of 56 patients with relapsed/refractory diffuse large B cell lymphoma were divided into control group and treatment group. The control group were received the conventional BACOD treatment, and the treatment group received continuous venoclysis with BACOD. Clinical efficacy was observed and compared.
RESULTSIn control group, 6 patients achieved CR, 9 patients achieved PR, and their overall remission rate was 53.6%. In treatment group, 10 patients achieved CR, 12 patients achieved PR, and their overall remission rate was 78.6%. The overall remission rate of treatment group was significantly higher than that of control group (χ2=3.903, P<0.05). The incidence rates of nausea and vomiting, thrombocytopenia, abnormal liver function, fever and granulocytopenia were not significant difference (P>0.05) between the two groups.
CONCLUSIONThe clinical efficacy of cyclophosphamide, vindesine and dexamethasone for treatment of patients with relapsed/refractory/diffuse large B cell lymphoma has been confirmed to be satisfactory, suggesting that the continuous venoclysis with BACOD can be apptied to the in clinical treatment.
